| Literature DB >> 33658502 |
Marie-Ming Aynaud1, J Javier Hernandez1,2,3, Seda Barutcu1, Ulrich Braunschweig2, Kin Chan1, Joel D Pearson1, Daniel Trcka1, Suzanna L Prosser1, Jaeyoun Kim1, Miriam Barrios-Rodiles1, Mark Jen1, Siyuan Song2,4, Jess Shen1, Christine Bruce5, Bryn Hazlett5, Susan Poutanen5, Liliana Attisano2,4, Rod Bremner1, Benjamin J Blencowe2,3, Tony Mazzulli5, Hong Han2, Laurence Pelletier6,7, Jeffrey L Wrana8,9.
Abstract
Population scale sweeps of viral pathogens, such as SARS-CoV-2, require high intensity testing for effective management. Here, we describe "Systematic Parallel Analysis of RNA coupled to Sequencing for Covid-19 screening" (C19-SPAR-Seq), a multiplexed, scalable, readily automated platform for SARS-CoV-2 detection that is capable of analyzing tens of thousands of patient samples in a single run. To address strict requirements for control of assay parameters and output demanded by clinical diagnostics, we employ a control-based Precision-Recall and Receiver Operator Characteristics (coPR) analysis to assign run-specific quality control metrics. C19-SPAR-Seq coupled to coPR on a trial cohort of several hundred patients performs with a specificity of 100% and sensitivity of 91% on samples with low viral loads, and a sensitivity of >95% on high viral loads associated with disease onset and peak transmissibility. This study establishes the feasibility of employing C19-SPAR-Seq for the large-scale monitoring of SARS-CoV-2 and other pathogens.Entities:
Year: 2021 PMID： 33658502 DOI： 10.1038/s41467-021-21653-y
Source DB: PubMed Journal: Nat Commun ISSN： 2041-1723 Impact factor: 14.919